H.C. Wainwright Sticks to Their Buy Rating for scPharmaceuticals (SCPH)

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on scPharmaceuticals (SCPHResearch Report) today and set a price target of $15.00. The company’s shares closed last Friday at $6.52.

Tsao covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, RVL Pharmaceuticals, and Roivant Sciences. According to TipRanks, Tsao has an average return of 1.2% and a 38.29% success rate on recommended stocks.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for scPharmaceuticals with a $10.33 average price target.

See the top stocks recommended by analysts >>

SCPH market cap is currently $178.7M and has a P/E ratio of -5.70.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

scPharmaceuticals, Inc.engages in the development of transformative pharmaceutical products for subcutaneous delivery. Its products include furosemide, used as parenteral diuretic in treating heart failure and ceftriaxone, used as parenteral antibiotic outside the hospital setting. The company was founded by Pieter Muntendam and Bertram Pitt in February 2013 and is headquartered in Burlington, MA.

Read More on SCPH:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More